Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018226674) TAU PHOSPHORYLATION INHIBITORS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

We claim:

1. A method for treating or preventing Alzheimer's disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the following:


69

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the compound is sb 206553 hydrochloride.

3. The method of claim 1, wherein the compound is sb 408124.

4. The method of claim 1, wherein the compound is nnc 55-0396 dihydrochloride.

5. The method of claim 1, wherein the compound is win 64338 hydrochloride.

6. The method of claim 1, wherein the compound is u-75302.

7. The method of claim 1, wherein the compound is rs 17053 hydrochloride.

8. The method of claim 1, wherein the compound is lfm-al3.

9. The method of claim 1, wherein the compound is PHA 665752.

10. The method of claim 1, wherein the compound is jk 184.

11. The method of claim 1, wherein the compound is cp 339818 hydrochloride.

12. The method of claim 1, wherein the compound is ch 223191.

13. The method of claim 1, wherein the compound is cgp-74514a hydrochloride.

14. The method of claim 1, wherein the compound is chr 2797.

15. The method of claim 1, wherein the compound is olaparib.

16. The method of claim 1, wherein the compound is chloroxine.

17. The method of any one of claims 1 to 16, further comprising administering to the subject an additional therapeutic agent.

18. The method of claim 17, wherein the additional therapeutic agent is selected from memantine, donepezil, galantamine, tacrine hydrochloride, and rivastigmine tartrate.

19. A method for inhibiting tau phosphorylation comprising administering to a subject a compound selected from the following:


73

or a pharmaceutically acceptable salt thereof.

20. The method of claim 19, wherein the compound is sb 206553 hydrochloride,

21. The method of claim 19, wherein the compound is sb 408124.

22. The method of claim 19, wherein the compound is nnc 55-0396 dihydrochloride.

23. The method of claim 19, wherein the compound is win 64338 hydrochloride,

24. The method of claim 19, wherein the compound is u-75302.

25. The method of claim 19, wherein the compound is rs 17053 hydrochloride.

26. The method of claim 19, wherein the compound is lfm-al3.

27. The method of claim 19, wherein the compound is PHA 665752.

28. The method of claim 19, wherein the compound is jk 184.

29. The method of claim 19, wherein the compound is cp 339818 hydrochloride,

30. The method of claim 19, wherein the compound is ch 223191.

31. The method of claim 19, wherein the compound is cgp-74514a hydrochloride.

32. The method of claim 19, wherein the compound is chr 2797.

33. The method of claim 19, wherein the compound is olaparib.

34. The method of claim 19, wherein the compound is chloroxine.

35. The method of any one of claims 19 to 34, further comprising administering to the subject an additional therapeutic agent.

36. The method of claim 35, wherein the additional therapeutic agent is selected from memantine, donepezil, galantamine, tacrine hydrochloride, and rivastigmine tartrate.

37. A method for inhibiting tau phosphorylation comprising administering to a subject a compound selected from the following:



or a pharmaceutically acceptable salt thereof.

38. The method of claim 37, wherein the compound is tegaserod maleate.

39. The method of claim 37, wherein the compound is perhexiline maleate.

40. The method of claim 37, wherein the compound is liothyronine sodium.

41. The method of claim 37, wherein the compound is dasatinib monohydrate.

42. The method of claim 37, wherein the compound is pazopanib hydrochloride.

43. The method of claim 37, wherein the compound is vemurafenib.

44. The method of claim 37, wherein the compound is artesunate.

45. The method of claim 37, wherein the compound is methylene blue.

46. The method of any one of claims 37 to 45, further comprising administering to the subject an additional therapeutic agent.

47. The method of claim 46, wherein the additional therapeutic agent is selected from memantine, donepezil, galantamine, tacrine hydrochloride, and rivastigmine tartrate.